Complicated peptic ulcer disease : prevention and treatment by Sverdén, Emma
From Department of Molecular Medicine and Surgery 
Karolinska Institutet, Stockholm, Sweden 
COMPLICATED PEPTIC ULCER DISEASE – PREVENTION AND TREATMENT 
Emma Sverdén, M.D. 
 
Stockholm 2017 
 
 Cover: "Quadroni of St. Charles", cathedral in Milan, Italy.  Giorgio Bonola (ca. 1657-1700) 
 
All previously published papers were reproduced with kind permission from the publishers, 
S. Karger AG, Basel, and Wolters Kluwer Health, Inc. 
 
Published by Karolinska Institutet. 
Printed by E-print AB 2017 
© Emma Sverdén, 2017 
ISBN 978-91-7676-626-2  
Complicated peptic ulcer disease – prevention and treatment  
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Emma Sverdén, M.D. 
Principal Supervisor: 
Professor Jesper Lagergren 
Karolinska Institutet 
Department of Molecular Medicine and 
Surgery  
and 
King’s College London 
Division of Cancer Studies 
 
Co-supervisor(s): 
Associate Professor Yunxia Lu 
University of California 
College of Health Sciences 
Program in Public Health 
 
Associate Professor Anders Sondén 
Karolinska Institutet 
Södersjukhuset 
Department of Clinical Research and 
Education 
 
Opponent: 
Professor Lars Aabakken 
Oslo University Hospital, Faculty of Medicine 
Department of Clinical Medicine 
 
Examination Board: 
Professor Jonas Manjer 
Lund University, Faculty of Medicine 
Department of Clinical Science 
 
Associate Professor Michael Fored 
Karolinska Institutet 
Department of Medicine 
 
Associate Professor Jakob Hedberg 
Uppsala University, Faculty of Medicine 
Department of Surgical Sciences 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Till Isa, Moa och Sigge 
  
  
  
ABSTRACT 
Peptic ulcer is a common disease worldwide and its complications can cause serious 
clinical problems. While the incidence of uncomplicated peptic ulcer disease is decreasing, 
the incidence of more complex ulcer disease is not. The most common complication is 
bleeding. Endoscopic intervention achieves haemostasis in most patients. The remaining 
part face a substantial risk of mortality and these patients have typically undergone more or 
less radical surgery. Transcatheter arterial embolisation (TAE) has emerged as a less 
invasive alternative to surgery, but there is limited scientific evidence supporting its role. 
The increased use of gastric bypass surgery for obesity has resulted in an increase in 
marginal ulcer, a complication of uncertain aetiology which is often difficult to heal. 
Helicobacter pylori (H. pylori) is the main risk factor for peptic ulcer, and eradication of 
this bacterium is an important part of the treatment. Yet, eradication after peptic ulcer is 
often delayed, with uncertain clinical consequences.  
This thesis aimed to help improve the treatment of peptic ulcer bleeding (Study I and II), 
identify risk factors for marginal ulcer (Study III), and clarify consequences of delayed H. 
pylori eradication after peptic ulcer diagnosis (Study IV). 
Study I compared mortality after a more radical with a minimal surgical approach for ulcer 
bleeding in a population-based cohort study using data from the Swedish Patient Registry 
in 1987-2008. The overall all-cause 5-year mortality was similar (hazard ratio [HR] 1.05, 
95% confidence interval [CI] 0.95-1.16), but was possibly higher following radical surgery 
from the year 2000 onwards (HR 1.27, 95% CI 0.99-1.63). 
Study II compared outcomes after TAE with surgery for ulcer bleeding in a cohort study in 
Stockholm County in 2000-2014, using data from medical records and the Swedish Patient 
Registry. Compared to the surgery group, the overall all-cause mortality was decreased in 
the TAE group (HR 0.66, 95% CI 0.46-0.96) as was the risk of complications (8.3% versus 
32.2%), and the median length of hospital stay (8 versus 16 days, adjusted acceleration 
factor 0.59, 95% CI 0.45-0.77). The risk of re-bleeding (HR 2.48, 95%CI 1.33-4.62) and re-
intervention (HR 5.41, 95% CI 2.49-11.76) was higher in the TAE group.  
Study III examined potential risk factors for marginal ulcer after gastric bypass surgery in a 
nationwide population-based cohort study using data from the Swedish Patient Registry in 
2006-2011. Diabetes (HR 1.26, 95% CI 1.03-1.55) and peptic ulcer history (2.70, 95% CI 
1.81-4.03) were associated with increased risk, while hyperlipidaemia, hypertension and 
chronic obstructive pulmonary disease were not. Use of aspirin and non-steroid anti-
inflammatory drugs (NSAIDs) below the median dose decreased the risk, while use of 
aspirin above the median dose entailed increased risk of marginal ulcer. Use of NSAID 
above the median did not influence the risk of marginal ulcer. Serotonin re-uptake inhibitor 
use below the median dose was associated with a decreased risk, while use above the 
median increased this risk.  
Study IV tested how various lengths of delays in H. pylori eradication after peptic ulcer 
diagnosis influenced outcomes in a population-based cohort study based on data from 
nationwide Swedish registries. Delays in eradication time-dependently increased the risk of 
ulcer recurrence, which was evident already after 8-30 days delay (HR 1.17, 95% CI 1.08-
1.25) and so was the risk of complicated ulcer (HR 1.55, 95% CI 1.35-1.78). Longer delays 
(61-365 days) also seemed to increase gastric cancer risk (HR 3.64, 95%CI 1.55-8.56). 
In conclusion: A less radical approach seems sufficient in the surgical treatment of ulcer 
bleedings. TAE could be recommended as a first-line therapy of peptic ulcer bleeding after 
failed endoscopic intervention. Diabetes, peptic ulcer history, and higher doses of anti-
inflammatory drugs seem to be risk factors for marginal ulcer. Delays in H. pylori 
eradication after peptic ulcer diagnosis must be avoided, since these might time-
dependently increase the risk of ulcer recurrence, ulcer complications and gastric cancer.  
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INTRODUCTION 
Peptic ulcer disease of today is mainly an issue for outpatient routine care. A typical patient 
is examined and diagnosed (based on endoscopy) in an outpatient setting, receives a short 
pharmacological treatment – with or without a follow-up examination – and after this, the 
patient is cured. This uncomplicated peptic ulcer disease is not the clinical issue addressed 
in this thesis. The scope of this work has instead been to shed some light on more complex 
forms of peptic ulcer disease. These are less common, but associated with considerable 
morbidity and mortality, as well as substantial costs for healthcare worldwide. Clinicians 
regularly face the challenge of quick decision-making in treating life-threatening bleedings 
from peptic ulcers. They also meet patients presenting with ulcers that arise after obesity 
surgery, that are difficult to heal, and of unclear aetiology. It is also our responsibility as 
clinicians to take all measures in order to prevent avoidable ulcer recurrences and further 
disease development leading to complications of ulcer disease, a task with great impact for 
the individual as well as for the public health care system. Some of these clinical issues are 
challenging to scientifically address. The aim of this doctoral project was to add some 
pieces to the puzzle that will lead to a better knowledge that can improve the treatment of 
complex ulcer disease.  
BACKGROUND 
HISTORY OF PEPTIC ULCER AND OF PEPTIC ULCER TREATMENT 
Peptic ulcer disease and peptic ulcer treatment were first scientifically described in the 
beginning of the 19th century. The aetiology and cure of this disease has then exercised 
many minds for the better part of two centuries. 
 
In 1823 it was shown in animal models that gastric acidity was caused by hydrochloric acid 
(HCl),1 and it was early recognised that damage was due to impaired resistance of the 
gastric mucosa to the corrosive properties of this acid. The treatment recommendations for 
peptic ulcer at this time, besides dietary advice and rest, were different kinds of antacids 
such as soda, magnesium, and chalk. This regimen persisted far into the 20th century. 
 
In 1938, a report of aspirin causing damage to the gastric mucosa was published.2 After the 
introduction of the first non-aspirin non-steroidal inflammatory drug (NSAID) in 1949, 
reports followed promptly of its association with peptic ulcers.3 4  
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Cimetidine, a histamine 2 (H2) receptor antagonist, was the first effective acid-suppressing 
drug, invented in 1971 and approved for clinical use in the late 1970s. The even more 
effective proton pump inhibitors (PPIs) were developed in the 1980s5 and the first drug in 
this category for prescription – omeprazole – was introduced in 1988. PPIs irreversibly 
block the gastric proton pump (the hydrogen/potassium adenosine triphosphatase enzyme 
system), which is the terminal stage in gastric acid secretion.  
 
In 1982 Warren and Marshall from Australia identified the association between the bacteria 
Helicobacter pylori (H. pylori) and peptic ulcer disease6. Recommendations that patients 
with ulcer disease and H. pylori infection should be treated with antibiotics came in the 
middle of the 1990s, which was when the insight that peptic ulcer disease is a curable 
infectious disease was starting to spread.  In 2005, Warren and Marshall were awarded the 
Nobel Prize in Physiology or Medicine for their important discovery. 
 
Surgery as a means to treat peptic ulcer disease has been reported since the late 19th 
century. Mikulicz-Radecki was one of the first surgeons to suture a peptic ulcer, and he also 
developed a precursor to the gastroscope. In 1881 Billroth reported the first successful 
gastric resection with reconstruction using a gastroduodenostomy for a tumour in pylorus, 
and the year after, Rydiger performed the first gastric resection for peptic ulcer disease.7 
Gastric resection with Billroth I or Billroth II reconstructions (Figure 1) became standard 
treatment of ulcer disease in the 1930s, driven by the insight that removing the distal part of 
the stomach promptly reduced acidity.  
 
Figure 1. Billroth I and Billroth II partial gastrectomies 
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Common complications following gastric resection were dumping syndrome and anaemia. 
Dumping syndrome is a constellation of symptoms due to hyperosmolar content emptying 
into the jejunum, causing for example abdominal pain, nausea, diarrhoea, and vasomotor 
symptoms such as fatigue, flushing, palpitations, perspiration, tachycardia, hypotension and 
sometimes syncope.8 Microcytic anaemia was common due to iron malabsorption caused 
by achlorhydria, macrocytic anaemia due to loss of parietal cells – leading to deficiency of 
intrinsic factor and decreased vitamin B12 absorption. There was also a considerable 
incidence of reported marginal (gastrojejunal) ulcers – up to 33% – that were located close 
to the anastomosis.9  
 
Vagal effects on acid secretion has been known since the beginning of the 20th century, but 
vagotomy as treatment for peptic ulcer disease was not described until 1946, by 
Dragstedt.10 He developed a technique for truncal vagotomy (Figure 2) with remarkably 
reducing effects on acidic gastric secretion.  
 
Figure 2. Truncal, selective and highly selective vagotomy 
 
Unfortunately, truncal vagotomy also caused hypotonicity of the stomach in more than 50% 
of the patients, leading to gastric outlet problems. This is the reason why Dragstedt later 
added the construction of a gastrojejunostomy to the procedure. A little more than 10% of 
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the patients had ulcer recurrence after truncal vagotomy.7 Later, developments of the 
method altered the gastrojejunostomy to a pyloroplasty, with the intention of avoiding 
gastric outlet problems while maintaining normal food pathway. Another adverse effect of 
vagotomy was diarrhoea, which was thought to be caused by denervation of the small 
bowel. In an attempt to reduce this problem, Frankson and Jackson 1948 suggested the use 
of selective vagotomy, saving branches to the celiac ganglion and anterior vagal nerve to 
the liver.11 Later, animal models showed that food and mechanical distention of the antrum 
caused increased gastric secretion. This effect was inhibited by a low pH, as a regulatory 
mechanism. In the end of the 1940s, vagotomies were therefore combined with antral 
resections, conserving 56-60% of the proximal stomach. Rates of ulcer recurrence were 
fairly low, and the method remained widely used until the end of the 20th century. An even 
more selective method, “parietal cell vagotomy” or “highly selective vagotomy” was 
introduced in the 1970s. It was technically more challenging, as it demanded careful 
removal of vagal fibres from the oesophagus. It denervated the parietal cell mass, but left 
the antrum innervated (Figure 2). 
 
Gastro-oesophageal endoscopy as a diagnostic tool was introduced in the early 1960s, when 
a student in physics and a gastroenterology trainee, Curtiss and Hirschowitz, developed the 
flexible fibre-optic endoscope.12 Techniques for endoscopic haemostatic intervention for 
bleeding peptic ulcers were described in the 1970s,13 and it became common clinical 
practice in the 1980s, defining a paradigm shift. Endoscopy is since then a mainstay in the 
treatment of bleeding peptic ulcers.  
 
In the 1990s, simply underrunning the ulcer became an option in emergency surgical 
treatment of peptic ulcer, combined with acid-supressing therapy and eradication of H. 
pylori. The need for planned peptic ulcer surgery was dramatically decreased after the 
introduction of effective medical treatment – H2-blockers, PPI and H. pylori eradication – 
and the evolution of endoscopic intervention. Emergency surgery for complications such as 
perforation and bleeding remained however, and has come to constitute the majority of all 
peptic ulcer surgery procedures.  
 
Treating peptic ulcer bleeding with interventional radiology started in the 1970s.14 
Transcatheter arterial embolisation (TAE) has gradually gained increased acceptance as an 
alternative to surgery in peptic ulcers with severe bleeding, and is currently widely used in 
clinical practice, at least in some centres. Figure 3 depicts frequencies of TAE and surgery 
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for peptic ulcer bleedings in Stockholm between 2000 and 2014. The introduction of an 
ambulatory 24-hour radiologic intervention service, is reflected in the increasing incidence 
of TAE in Stockholm from 2007 and onwards. 
 
 Figure 3. Changes in the use of surgery versus TAE for peptic ulcer bleeding between 
2000 and 2014 in Stockholm County 
 
 
ANATOMY AND PHYSIOLOGY OF THE STOMACH AND THE DUODENUM  
 
Anatomy 
The stomach can be divided into the cardia, fundus, corpus, antrum, and pylorus (Figure 4). 
The cardia is the proximal area where the oesophagus and the stomach connect. To the left 
of the cardia is the fundus. Below the fundus is the corpus, which is the largest part of the 
stomach. The greater curvature, or major side, is the convex left part of the stomach. The 
lesser curvature, or minor side, is the right concave part. The antrum is a more distal part 
of the stomach. The pylorus is an opening with a smooth muscle sphincter that connects 
the stomach to the duodenum.  
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Figure 4. Anatomy of the stomach 15 
 
Figure 5. Anatomy of the duodenum15 
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Figure 5 depicts the first part of the small intestine – the duodenum. The duodenum starts at 
the pylorus and reaches to the ligament of Treitz, and it can be divided into four parts. The 
superior part, measuring approximately 5 centimetres, begins at the pylorus, and its first 
part of 2-3 centimetres is called the duodenal bulb. The superior part then passes beneath 
the liver, becoming the descending part of the duodenum. The descending part takes a 
curve and goes downwards along the pancreatic head. This is the part where the common 
bile duct and the pancreatic duct enter the medial side of the duodenum, at the major papilla 
(papilla Vateri). The duodenum then turns medially again and becomes the horizontal 
part, passing across the spinal column while inclining upward for about 5–8 centimetres. 
The ascending part begins to the left of the spinal column. It ascends on the left side of the 
aorta for another couple of centimetres, and then it reaches the ligament of Treitz, where 
the jejunum starts. 
Blood supply  
The stomach is well supplied with blood flow from various large vessels that communicate 
with each other (Figure 6), which makes the organ easy to resect with secured oxygenation. 
The major side is supplied with blood from the left and right gastroepiploic arteries. The 
upper portion of the major side and the fundus also receives blood from the short gastric 
arteries. The minor side is supplied from the left gastric artery – which also supplies the 
cardiac region – and from the right gastric artery. The gastroduodenal artery supplies blood 
to the distal part of the pylorus and to the proximal duodenum, and to the major side of the 
stomach. There is also a branch from the superior mesenteric artery supplying the 
duodenum, the inferior pancreaticoduodenal artery.  
 
Histology  
The stomach and the duodenum consist of four layers (Figure 7): 
1. The mucosa is the inner lining, containing epithelial cells, lamina propria (loose 
connective tissue) and muscularis mucosae (very thin muscular layer). 
2. The submucosa, consisting of connective tissue with blood vessels, lymph vessels, and 
nerve cells. 
3. The muscularis externa (or muscularis propria) consists of 3 different layers of muscle in 
the stomach. 
4. The serosa is a fibrous membrane, covering the outside of the stomach and the duodenum. 
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Figure 6. Blood supply of the stomach and the duodenum 
 
 
Figure 7. Histology of the stomach15 
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Physiology  
There are several cell types in the stomach (Figure 7). In the cardia, the glands secrete 
mainly mucus and bicarbonate. The parietal-, chief-, enterochromaffin-like-, and D-cells 
reside mainly in the fundus and corpus. The majority of parietal cells are localised in the 
corpus. The antrum contains mostly G cells and D cells, which are so called 
enteroendocrine cells.16 Parietal cells are highly differentiated epithelial cells that produce 
hydrochloric acid (HCl), responsible for the high acidity (pH 1.5 - 3.5) of the stomach. HCl 
is also needed to activate pepsin, which is an enzyme needed for protein digestion. In 
addition, HCl has anti-bacterial effects. The parietal cells also produce intrinsic factor, a 
protein that is necessary for the absorption of vitamin B12 in the small intestine. Chief 
cells secrete pepsinogen, the inactive form of pepsin. Enterochromaffin-like cells 
synthesise and secrete histamine. Enteroendocrine cells secrete various hormones, 
including gastrin, which is released mainly by G cells, and somatostatin produced by D-
cells. 
HCl secretion from parietal cells is under hormonal and nervous control. The major stimulus 
of acid secretion is gastrin, which mediates the so called gastric phase of secretion. Gastrin 
probably does not stimulate the parietal cells directly, but acts to mobilise histamine from the 
enterochromaffin-like cells in the mucosa.17 Histamine then stimulates the parietal cells to 
secrete HCl. Parietal cells can also produce HCl in response to acetylcholine stimulation from 
the vagal nerve, protein ingestion, and distension of the stomach. The primary transporter 
responsible for the acidity of the stomach is the H+/K+ ATPase, also called the proton 
pump, which is located on the surface of the cell. Parietal cells secrete a proton (H+) into the 
lumen of the stomach in exchange of a potassium ion (K+). There is also a negative 
regulation of secretion, mediated by somatostatin. A low pH in the antrum stimulates release 
of somatostatin from the D cells, which exert inhibitory control of gastrin release from the G 
cells.  
The acidic environment in the stomach functions as protection against microbes. The 
gastric mucosa is protected from the acid by high turnover, tight junctions, mucus, and 
bicarbonate secretion. If the protective mechanisms of the mucosa are overwhelmed by the 
damaging effects of gastric acid and pepsin, ulcer formation and other pathology can occur. 
It has been shown that a low intragastric pH activates pepsin, which can dissolve clots at a 
site of mucosal damage. The acidic environment also inhibits platelet function.18  
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The duodenum has a villous mucosa, which increases the surface area and facilitates 
absorption of nutrients. Brunner´s glands in the duodenal mucosa secrete mucus with a high 
concentration of alkaline bicarbonate that neutralises the acid from the stomach. In 
response to stimuli from acid and fat-containing food, neural reflexes and prostaglandin 
production mediate both an increase in alkaline secretion from cells in duodenum, and the 
release of cholecystokinin and secretin. These hormones stimulate the secretion of bile and 
pancreatic enzymes into the intestinal lumen.  
 
PEPTIC ULCERS, DEFINITION AND AETIOLOGY  
A peptic ulcer is endoscopically usually defined as a mucosal break in the stomach or 
duodenum, more than 3mm (some would argue 5mm) in diameter, with a visible depth. 
Histologically, an ulcer is defined as a break through the muscularis mucosae. If it breaches 
only through the lamina propria mucosae, or if it is smaller than 3-5 mm, it is instead called 
an erosion.19 Complications of peptic ulcer include bleeding, perforation, penetration (to 
another organ), and obstruction (from stricturing). Bleeding from a peptic ulcer occurs 
when an ulcer erodes an underlying vessel. Perforation or penetration of a peptic ulcer 
means that the entire wall of the stomach and duodenum is breached. Obstruction with 
fibrotic strictures occurs mainly in the pyloric region, often due to chronic ulceration and 
inflammation.  
 
Acid is no longer regarded dominant in the causal chain of peptic ulcer formation. Instead, 
it is a well-established fact that the two most common causes of peptic ulcer are infection 
with the bacteria H. pylori, and the use of NSAIDs. 20 21 Smoking is another well-
established risk factor,22 whereas psychological stress is probably not an important risk 
factor, even though some researchers have found a weak association.23 “Stress ulcerations” 
refer to ulcers that occur during physiological stress such as trauma, major operative 
procedures, injury of the central nervous system, and during critical illness. Alcohol and 
coffee seem not to be causal risk factors.24 Among uncommon causes of peptic ulcers are 
the Zollinger-Ellison syndrome with excessive hydrochloric acid production due to gastrin 
secretion, infections, and certain systemic diseases. Cameron ulcers are ulcers in a hiatal 
hernia where the stomach passes through the diaphragm. Marginal ulcers can appear after 
gastric resection, or after bypass surgery. These ulcers are usually situated on the jejunal 
side of the anastomosis. 
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Peptic ulcer and Helicobacter pylori 
H. pylori is a spiral-shaped gram-negative bacterium, which colonises the stomach of 
about 50% of the people in the world. In some countries, the prevalence is well over 
70%.25 Intra-familial oral transmission is considered common.26 H. pylori invades 
the mucosa, and is considered to be responsible for more than 90% of duodenal 
ulcers and more than 70% of all gastric ulcers. H. pylori is diagnosed by histological 
test at endoscopy, breath test, serology, or by stool-antigen test. The sensitivity and 
specificity of the tests vary, as depicted in Table 1.  
 
Table 1. Different tests to identify H. Pylori 27 
Test Indication Comments 
Sensi-     
tivity (%) 
Speci-     
ficity (%) 
Reference 
Non-invasive tests 
Urea breath 
test 
Primary diagnosis, 
eradication control 
Accurate, 
practical, 
available 
95 98 
Leodolter 
28 
Monoclonal 
stool 
antigen 
Primary diagnosis, 
eradication control 
Available, 
requires 
refrigeration of 
samples 
94 97 Gisbert29 
Polyclonal 
stool 
antigen 
Primary diagnosis, 
eradication control 
Available, 
requires 
refrigeration of 
samples 
91 93 Gisbert30 
Serological 
testing 
Not after treatment 
Available, 
inexpensive, 
good negative 
predictive values 
85 79 Loy31 
Office 
based blood 
test 
Not advised Low accuracy 71 88 Vaira32 
Biopsy-based tests 
Histology 
Additional 
information on 
gastritis, atrophy, 
dysplasia 
Expensive, 
requires trained 
staff 
93 99 Cutler33 
Rapid 
urease test 
Primary diagnosis 
if endoscopy 
required 
Inexpensive; 
rapid 
90 95 Vaira32 
Culture 
Antibiotic 
susceptibility 
testing 
Excellent 
specificity, 
expensive, 
limited 
availability, slow 
growth 
73 100 Grove34 
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The Maastricht V Consensus Report from 2012 recommended the rapid urease test (RUT) 
at endoscopy as the first choice to identify H. pylori.35  It has been shown that ulcer 
bleeding makes H. pylori diagnosis more difficult to detect. A prospective study from 
South Korea found that bleeding decreased the sensitivity of the rapid urease test from 96% 
to 85%.36 Use of proton pump inhibitors can make the bacteria go into a coccoid form, 
which can give false negative test results. For that reason, it is recommended to withdraw 
such medication two weeks before testing. New techniques for diagnosis are under 
development, including different kinds of enhanced endoscopic imaging techniques.  
 
H. pylori infection is also a well-established risk factor for gastric cancer.37 In 2014, the 
World Health Organisation (WHO) reported a strategy of preventing gastric cancer through 
eradication of H. pylori. The report stated that gastric cancer was the third leading cause of 
cancer deaths worldwide, and that 80% of the 1 million new cases each year were caused 
by H. pylori.38 A presumed mechanism for this is that the release of pro-inflammatory and 
acid-suppressive cytokines from the parietal cells induce gastritis, mobilisation of 
suppressor cells, dysplasia and cancer. The cancer risk is more strongly associated with 
gastric ulcers than with ulcers of the duodenum.39 40 There is also a substantial variability 
regarding the strength of the association between H. pylori and gastric cancer between 
different populations, which could be due to factors that influence the interaction between 
the bacteria and host, i.e. human genetic polymorphisms, environmental factors and the 
high genomic diversity of H. pylori. 
 
Peptic ulcer disease is associated with histologically proven gastritis. In patients with 
duodenal ulcers, studies show that the gastritis is localised primarily to the antrum,41 which 
differs from the pattern in patients with gastric ulcer or in patients with gastritis, but no 
ulcer. In gastric ulcer patients, there is a gradual extension of the gastritis from the antrum 
into the corpus, which eventually leads to loss of parietal cells and development of atrophy. 
The gradual increase of gastritis leads to decreased acid secretion. When it was discovered 
that vagotomy was associated with a rather rapid extension of gastritis into the corpus, it 
was concluded that acid secretion could be responsible for protecting the corpus from 
atrophic gastritis, possibly by inhibiting the effect of H. pylori on further extension of 
gastritis. A conclusion was that also pharmacological acid suppression could lead to 
accelerated corpus gastritis caused by H. pylori.42 Development of atrophic gastritis and 
potentially gastric cancer can thus be enhanced by profound acid suppression in the 
presence of H. pylori.43 
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There is convincing evidence that eradication of H. pylori after a peptic ulcer bleeding 
significantly decreases risk of recurrence.44 Studies have also shown that such eradication 
promotes duodenal ulcer healing and prevents recurrence of duodenal ulcers in general45 
and that it decreases recurrence rate for gastric ulcers.46  The treatment recommendations 
for H. pylori differ between countries, mainly depending on the status of local antibiotic 
resistance. In Sweden, the first line treatment is presently clarithromycin plus 
metronidazole for one week in combination with a proton pump inhibitor. Follow-up tests, 
for example with urea breath test, is not routinely recommended in Sweden today, due to 
the low incidence of antibiotic resistance.  
 
Peptic ulcer and non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly 
prescribed drugs in the world, used because of their analgetic and anti-inflammatory 
effects.47 Aspirin is often discussed as an entity of its own, but is sometimes also included 
in this group of drugs. NSAIDs, as well as aspirin, suppress the production of 
prostaglandins by inhibiting cyclooxygenase (COX), an enzyme required for prostaglandin 
biosynthesis. Prostaglandins mediate inflammation, and can also inhibit gastric acid 
secretion, stimulate mucus and bicarbonate secretion, as well as increase mucosal blood 
flow.48 Aspirin also has pronounced antiplatelet properties, which is the reason for its 
widespread use in primary and secondary prevention of cardiovascular disease. Aspirin use 
is more common among men, while there is a female predominance among NSAID users. 
The use of aspirin and NSAIDs has increased during the last decades. In 2010, the use of 
aspirin and NSAIDs in the United States had increased by 57% and 43%, respectively, over 
a 5-year period, and 46% of all adults over 70 years reported using aspirin regularly.47 
 
NSAID-users have an increased incidence of both duodenal and gastric ulcers, occurring in 
approximately 10% and 14%, respectively, and the incidence is even higher among long-
term users.49 50 Cyklo-oxygenase (Cox)-2 selective NSAIDs are associated with a lower 
degree of ulcer formation compared to non-selective NSAIDs,51 but they are associated 
with an increased risk of cardiovascular disease. 
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OCCURRENCE OF PEPTIC ULCER  
Incidence of peptic ulcers, and of peptic ulcer bleeding 
The overall incidence of uncomplicated peptic ulcer disease has been decreasing in recent 
years. A systematic review from 2009 examining the incidence in western countries, 
reported an annual incidence of 0.10-0.19%.52 A corresponding decrease in the incidence of 
complicated peptic ulcer disease, as well as of mortality, could be expected, but these 
outcomes do not seem to decrease at the same pace. Published data on incidence and 
mortality for complicated peptic ulcer disease show contradictory results, and there is 
substantial variability between different countries.53 The most frequent complication of 
peptic ulcers is bleeding. The reported annual incidence rate of peptic ulcer bleeding in the 
general population ranged from 19 to 57 cases per 100,000 individuals (0.02-0.06%) in a 
systematic review from 2011, based mainly on studies from Europe.54 In Sweden, the 
incidence rate of peptic ulcer bleeding was reported to be 38 per 100,000 individuals in 
2005 (0.04%).55  
 
Incidence of marginal ulcer 
Obesity is one of the leading public health concerns in the world today. WHO reported in 
2014 that 13% of adults worldwide – about 600 million people – were obese (BMI >30), 
and the prevalence has more than doubled in 30 years.56 Surgery has proven to be an 
effective treatment for severe obesity with subsequent remission of several obesity-related 
comorbidities, and improved quality of life and survival.57 The estimated number of 
surgical procedures for obesity worldwide was 468,609 in 2013, and the most common 
procedure was gastric bypass (45%), usually performed with a laparoscopic approach 
(Figure 8).58 Furthermore, it is estimated that only <1% of eligible people with severe 
obesity are undergoing surgery today, which indicates that the use of these procedures 
might further increase within the foreseeable future.   
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Figure 8. Gastric bypass (illustration by Rebecka Zacharias) 
One of the most common complications of gastric bypass surgery is a marginal ulcer, 
which has been estimated to occur in around 5% of patients.59 These ulcers are almost 
always located on the jejunal side of the anastomosis. The underlying mechanisms are 
unclear, but impaired microcirculation and different inflammatory mechanisms have been 
suggested. Efforts have been made to prevent marginal ulcer by screening for H. pylori and 
treat all who test positive with eradication therapy in combination with prophylactic PPI-
treatment for several months. Even with these precautions, 2.3% of the patients developed 
marginal ulcer after a mean follow-up time of 15 months.60 Of these, 44.1% required 
surgical intervention.  
CURRENT TREATMENT  
Treatment of peptic ulcer disease 
All patients diagnosed with peptic ulcers should be tested for H. pylori. If positive, 
eradication therapy is indicated.44 In Sweden however, guidelines usually recommend 
eradication therapy to all duodenal ulcers without prior testing, since >90% of these ulcers 
are considered to be caused by H. pylori. If the patient has received eradication therapy 
previously, a diagnostic test is advised to confirm the diagnosis. The eradication therapy 
consists of a combination of at least two antibiotics and one PPI, the latter is used to 
accelerate the healing process. For uncomplicated duodenal ulcers, there is no need for 
continued PPI after the eradication therapy. For gastric ulcers, PPI treatment should last for 
up to 8 weeks, due to the slower healing of these ulcers.61 Gastric ulcers should also be 
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followed up with repeat endoscopies until healed, mainly because some of these ulcers 
could be misdiagnosed gastric cancers. 
 
Treatment of peptic ulcer bleeding 
In patients who present with upper gastrointestinal bleeding, the first action is resuscitation. 
Volume replacement should mainly be obtained by crystalloids62. A restrictive transfusion 
strategy is recommended, with a target haemoglobin (Hb) level of 70-90 g/L.63 For patients 
with ischemic heart disease, a higher target Hb could be considered. The European Society 
of Gastrointestinal Endoscopy (ESGE) recommends prompt injection with high-dose 
intravenous PPI, followed by infusion for 3 days in cases of substantial bleeding. A 
Cochrane meta-analysis has shown a significant decrease in bleeding stigmata and need for 
endoscopic intervention following early intravenous treatment with PPI, even if no 
significant differences in re-bleeding or mortality could be detected.64 The issue of 
continuous PPI-infusion after endoscopy is under debate. A recent re-assessment of a 
randomised multi-centre trial found low re-bleeding rates among Forrest Ib ulcers after 
endoscopic treatment, irrespective of PPI or placebo treatment.65  There is no evidence to 
support the use of Tranexamic acid.66 67 There is also uncertainty whether Tranexamic acid 
could increase the risk of cardiovascular or thromboembolic, since many of these patients 
have a history of cardiovascular disease and stroke.68. Intravenous erythromycin is 
recommended as a single dose in order to promote gastric emptying and improve 
endoscopic visualisation.69 It is recommended to use a scoring system for risk stratification, 
preferably the Glasgow-Blatchford Score.70 Early endoscopy (within 24 hours of in-
hospitalisation) is recommended.71 If the patient is unstable despite resuscitation, 
endoscopy should be performed without delay.  
Table 2. Forrest classification in relation to risk of re-bleeding after endoscopy 
  Forrest grade Prevalence* Re-bleeding* Surgery* Mortality* 
Spurting bleed Forrest Ia 
18% 55% 35% 11% 
Oozing bleed Forrest Ib 
Non-bleeding 
visible vessel 
Forrest IIa 17% 43% 34% 11% 
Adherent clot Forrest IIb 17% 22% 10% 7% 
Flat haematin spot Forrest IIc  20% 10% 6% 3% 
Fibrin-covered 
clean base 
Forrest III 42% 5% 0.5% 2% 
*All data from prospective trials where no patients received endoscopic therapy72  
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At endoscopy, peptic ulcers should be classified according to the Forrest classification, as a 
means of deciding whether there is an indication for endoscopic intervention (Table 2).72  
Ulcers with ongoing bleeding or high risk features of re-bleeding (Forrest grade Ia, Ib and 
IIa), are qualified for intervention due to their substantial risk of recurrent bleeding, as 
shown in Table 2. Regarding adherent clots (Forrest grade IIb), it is usually suggested to 
remove the clot if possible73, since many of these ulcers then can be re-classified to Forrest 
IIa. Whether to treat a clot that is not removable, is under debate.74 Endoscopic intervention 
should consist of a dual therapy with epinephrine injection in combination with either clips, 
a thermal method or an injection method.75 76 Novel methods exist, for example haemostatic 
powder, but these need further evaluation.77 Second-look endoscopy after initial 
haemostasis following endoscopy is not recommended,78 unless the patient shows clinical 
signs of re-bleeding. Patients with Forrest grade Ia-IIa ulcers, as well as IIb ulcers that have 
not received endoscopic treatment, should have continuous PPI-infusion for 72 hours. If the 
patient re-bleeds, a second attempt of endoscopy is recommended. If the bleeding persists, 
the ESGE recommends transcatheter angiographic embolisation (TAE) or surgery. 
Bleeding ulcer patients should be tested for H. pylori. If the test is negative in the acute 
setting, re-testing should be performed. Aspirin as secondary prophylaxis for cardiovascular 
disease should not be discontinued in patients with Forrest grade IIc-III. Patients with 
Forrest grade Ia-IIb are recommended to resume aspirin 3 days after haemostasis.63 
NSAID-treatment should be withdrawn if possible. If not, treatment with a COX-2 inhibitor 
seems as effective as combining a regular NSAID with PPI, with respect to the prevention 
of recurrent bleeding.79 
 
Treatment of marginal ulcer 
Since the incidence of marginal ulcer has been shown to be 27-36% in symptomatic 
patients after gastric bypass,80 early endoscopy is recommendable for all patients with 
symptoms like epigastric pain, nausea, vomiting, or dysphagia. There is no treatment 
tailored for marginal ulcer. It is recommended to eliminate plausible risk factors, such as 
tobacco smoking, and to initiate PPI-treatment. There is no consensus or real evidence 
regarding dosage of PPI, but a high-dose regimen is usually recommended until healing is 
obtained.81 These patients should be followed with repeat endoscopies until the ulcer is 
healed. There is no well-established strategy for secondary prevention after treatment for 
marginal ulcer. 
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AIMS OF THE THESIS 
 
The overall aim of this thesis was to compare treatment options for complicated peptic 
ulcer, to find risk factors for marginal ulcers after gastric bypass surgery, and to investigate 
the consequences of non-adherence to follow-up recommendations regarding H. pylori 
eradication after peptic ulcer disease.  
 
The specific aims were: 
• To compare mortality after more and less extensive surgery for peptic ulcer 
bleeding 
• To compare mortality, risk of re-bleeding, length of hospital stay and complication 
rates after transcatheter arterial embolisation with surgery for peptic ulcer bleeding 
when endoscopic intervention fails to stop the bleeding 
• To evaluate risk of marginal ulcer after gastric bypass surgery in relation to 
diabetes, hyperlipidaemia, hypertension, chronic obstructive pulmonary disease 
(COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, nonsteroidal 
anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors 
(SSRIs) 
• To test how various lengths of time delays in H. pylori eradication following peptic 
ulcer diagnosis influence the risk of recurrent ulcer, ulcer complications, and gastric 
cancer 
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METHODS 
STUDY OVERVIEW 
  Study I Study II Study III Study IV 
Short title 
Minimal versus 
definitive surgery 
for peptic ulcer 
bleeding 
Transcatheter 
arterial 
embolisation versus 
surgery for 
uncontrolled peptic 
ulcer bleeding 
Risk factors for 
marginal ulcer after 
gastric bypass 
surgery for obesity 
Ulcer and cancer 
risk following 
delays in H. pylori 
eradication  
Study design 
Population-based 
cohort study 
Population-based 
cohort study 
Population-based 
cohort study 
Population-based 
cohort study 
Data sources 
Swedish Patient 
Registry, Swedish 
Causes of Death 
Registry, Registry 
of the Total 
Population 
Swedish Patient 
Registry, Local 
Hospital Registries, 
Medical records 
Swedish Patient 
Registry, Swedish 
Prescribed Drug 
Registry, Registry 
of the Total 
Population 
Swedish Patient 
Registry, Swedish 
Prescribed Drug 
Registry, Swedish 
Cancer Registry 
Source 
population 
All adults in 
Sweden 
undergoing 
surgery for 
bleeding peptic 
ulcer during the 
study period 
All adults in 
Stockholm county 
undergoing TAE or 
surgery for 
bleeding peptic 
ulcer during the 
study period 
All adults in 
Sweden undergoing 
gastric bypass 
surgery during the 
study period 
All adults in 
Sweden receiving 
prescription for H. 
pylori eradication 
after peptic ulcer 
diagnosis during 
the study period 
Study period 1987 - 2008 2000 - 2014 2006 - 2011 2005 - 2013 
Sample size 4131 individuals 282 individuals 20,294 individuals 29,032 individuals 
Exposure 
Minimal or 
definitive surgery 
for peptic ulcer 
bleeding 
TAE or surgery for 
peptic ulcer 
bleeding 
Diabetes, 
hyperlipidaemia, 
hypertension, 
COPD, ulcer 
history, PPI, 
aspirin, NSAID, 
SSRI 
Predefined delays 
of H. pylori 
eradication: ≤7d, 
31-60d, >365d 
Outcome 
Risk of all-cause 
overall mortality, 
and all-cause 
mortality within 
30 days, 90 days, 
1y, and 5 y of 
surgery 
1. All-cause 
mortality, 30d, 90d, 
1y, and 5y  
2. In-hospital re-
bleeding  
3. Duration of 
hospital stay 
Marginal ulcer after 
gastric bypass 
surgery 
1. Recurrence of 
peptic ulcer  
2. Peptic ulcer 
complication  
3. Gastric cancer 
Main 
statistical 
methods 
Multivariable Cox 
regression, 
propensity score 
model  
Multivariable Cox 
regression, 
parametric 
accelerated failure 
time models 
Multivariable Cox 
regression  
Multivariable Cox 
regression  
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DATA SOURCES 
Study I, III and IV are based entirely on data from Swedish national healthcare registries. 
Study II also uses local hospital registries, and on medical records. Linkage between 
registries, and between registries and medical records, was possible by using the Swedish 
personal 10-digit identity number, which uniquely identifies all Swedish residents.82 
 
The Swedish Patient Registry 
The Patient Registry was established in 1964, and contains complete nationwide data of in-
hospital care in Sweden since 1987.83 Since 2001, the registry also contains complete data 
of specialist outpatient care and day surgery, including both private and public caregivers. 
Diagnosis codes at discharge, codes of surgical procedures and hospitalisation dates are 
among the data that can be obtained. Validation studies have shown that 85-95% of 
diagnoses are valid,84 and codes representing upper gastrointestinal surgery have been 
shown to have up to 99.6% positive predictive value.85 The diagnoses are coded according 
to the International Classification of Diseases (ICD) versions 9 and 10.  
 
The Swedish Cancer Registry 
The Cancer Registry was established in 1958. It has 98% complete registration of type and 
date of gastric cancer diagnoses in Sweden according to a validation study from our 
group.86 
 
The Swedish Causes of Death Registry 
The Causes of Death Registry was established in 1961 in its current shape. It collects 
information about all deaths among Swedish residents and is believed to have a 99% 
coverage.87 
 
The Swedish Prescribed Drug Registry 
The Prescribed Drug Registry records all prescribed and dispensed drugs in Sweden since 
1st July 2005.88 The registry contains information on names of prescribed drug substances 
according to the anatomical therapeutic chemical classification (ATC).88 It also contains 
information about dose and amount of each prescribed drug. 
 
The Swedish Registry of the Total Population 
This Registry of the Total Population was established in 1968 and provides complete 
information on dates of birth, death, and migration in Sweden. 
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STUDY DESIGN AND METHODS 
All studies included in this thesis were population-based cohort studies in design. 
 
Study I 
To compare mortality after less and more extensive surgery for peptic ulcer bleeding, Study 
I used data from the Swedish Patient Registry to identify all adult patients undergoing 
surgery for peptic ulcer bleeding between 1987 and 2008. We used the International 
Classification of Diseases (ICD) version 9 and 10 codes for peptic ulcer bleeding, and the 
Nordic Medico-Statistical Committee (NOMESCO) codes for identifying the relevant 
surgical procedures. Less extensive surgery was defined as under-running of the ulcer 
through a gastrotomy or duodenotomy with or without ligation of the major source artery 
and/or local excision of the ulcer. More extensive surgery was defined as resection of a part 
of the stomach or duodenum, with or without vagotomy. The Swedish Patient Registry was 
also used to identify comorbidities, and to identify if the hospital was a high volume, 
medium volume, or low volume centre for these procedures. Calendar period was taken 
into account by dividing the cohort into an early and a late period, analysed separately. 
Outcomes were all-cause overall mortality, and 30-day, 90-day, 1-year, and 5-year all-
cause mortality. 
 
Study II 
To compare key outcomes following transcatheter arterial embolisation (TAE) with 
conventional surgery for uncontrolled peptic ulcer bleeding, study IV identified patients 
undergoing TAE or surgery for peptic ulcer bleeding in Stockholm County between the 
years 2000 and 2014. Patients undergoing TAE were further evaluated through local 
hospital registries at the radiology departments. This procedure does not have an 
established code in the Patient Registry. The registries used were the administrative sources 
on which the radiology departments get economic compensation for their examinations and 
interventions. All the departments used digitalised recording and patients have to be 
registered in the system with their personal identity number in order to initiate an 
examination or intervention. These individuals were then linked to the Patient Registry to 
identify those who had a peptic ulcer diagnosis at the same hospitalisation. All medical 
records for patients having undergone abdominal angiography at the time of hospitalisation 
for peptic ulcer were scrutinised by the author of this thesis, and patients with other 
indications for angiography than peptic ulcer bleeding were excluded. Patients undergoing 
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surgery were identified through the Patient Registry. In patients who underwent both TAE 
and surgery, the first intervention after endoscopy was assigned to the individual. The 
primary outcome was all-cause mortality, occurring within 30 days, 90 days, 1 year, and 5 
years after the intervention. Secondary outcomes were in-hospital re-bleeding, re-
intervention, duration of hospitalisation, and complications.  
 
Study III 
To assess risk factors for marginal ulcer after gastric bypass surgery, study II used the 
Patient Registry to identify all adult patients who underwent gastric bypass in Sweden 
between 2006 and 2011. The Patient Registry and the Prescribed Drug Registry were then 
used to identify the presence of any of 9 potential risk factors that were under study: 
diabetes, hyperlipidaemia, hypertension, chronic obstructive pulmonary disease, ulcer 
history, and use of proton pump inhibitors (PPIs), aspirin, non-steroidal anti-inflammatory 
drugs (NSAIDs), and selective serotonin re-uptake inhibitors (SSRIs). The study outcome 
was the development of marginal ulcer.  
 
Study IV 
To test how various lengths of delays in H. pylori eradication influence the risk of recurrent 
peptic ulcer, ulcer complications (bleeding or perforation) and gastric cancer, Study IV 
used the Patient Registry and the Prescribed Drugs Registry to identify all adults in Sweden 
that were diagnosed with peptic ulcer and who were prescribed eradication therapy for H. 
pylori between the years 2005 and 2013. Pre-defined time latency intervals between peptic 
ulcer diagnosis and H. pylori eradication were analysed in relation to the study outcomes.  
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STATISTICAL ANALYSES 
Associations between exposures and outcomes in all studies were estimated using 
multivariable Cox proportional hazard regression models, which provided hazard ratios 
(HRs) and 95% confidence intervals (CIs), adjusted for pre-selected potential confounders. In 
Study I, an additional propensity score matched analysis was conducted since the hazards 
assumptions were not entirely met. In study II additional parametric accelerated failure time 
models were used to estimate the association between TAE or surgery and the outcome 
length of hospital stay, expressed as acceleration factor (AF) and 95% CI. 
 
ETHICAL CONSIDERATIONS 
All studies in this thesis were approved by the Regional Ethical Review Board in 
Stockholm. Study I, III and IV are strictly register-based, with study subject being 
anonymous to the researcher. Study II included manual review of medical records, but data 
were analysed and presented at a group level. Data storage, management and analyses have 
been performed on firewall- and password protected servers at Karolinska Institutet. Discs 
were stored in locked safes located in constantly locked offices, accessed only by a 
personal key card with password. 
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RESULTS AND CONCLUSIONS 
 
Study I 
Among 4163 patients having undergone surgery for peptic ulcer during the study period, 
2132 (51.2%) underwent less extensive surgery and 2031 (48.8%) underwent more 
extensive surgery for peptic ulcer bleeding. When comparing these groups, no differences 
in all-cause overall mortality were identified. Using the less extensive surgery group as the 
reference, the HRs for mortality in the more extensive surgery group within 30 days, 90 
days, 1 year, and 5 years were 0.87 (95% CI 0.72-1.05), 0.93 (0.80-1.09), 1.00 (95% CI 
0.87-1.14), and 1.05 (95% CI 0.95-1.16), respectively. No statistically significant 
differences in mortality were found when analysing the calendar period before and after 
year 2000 separately, but a trend towards better survival for minimal surgery was indicated 
in the late period (Table 3). In the later calendar period, using the less extensive surgery 
group as the reference, the HRs for death in the more extensive surgery group within 30 
days, 90 days, 1 year, and 5 years were 1.05 (95% CI 0.65-1.69), 1.18 (95% CI 0.81-1.73), 
1.17 (0.84-1.62), and 1.27 (95% CI 0.99-1.63), respectively. The estimates of the 
propensity score model were similar.  
Thus, a minimal approach is probably sufficient in most cases of peptic ulcer bleedings 
requiring surgery. 
 
Table 3. Risk of all-cause mortality after surgery for peptic ulcer bleeding before and after year 
2000, expressed as hazard ratios with 95% confidence intervals  
 
Regression model* Propensity score model** 
  Minimal surgery Definitive surgery Minimal surgery Definitive surgery 
  HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Before year 2000 
      
30-day 1.00 (Reference) 0.84 (0.69 -1.02) 1.00 (Reference) 0.92 (0.74-1.14) 
90-day 1.00 (Reference) 0.90 (0.76 -1.06) 1.00 (Reference) 0.94 (0.78-1.12) 
1-year 1.00 (Reference) 0.97 (0.84 -1.12) 1.00 (Reference) 1.02 (0.87-1.20) 
5-year 1.00 (Reference) 1.03 (0.92 -1.14) 1.00 (Reference) 1.04 (0.93-1.18) 
 
        After year 2000 
     30-day 1.00 (Reference) 1.05 (0.65-1.69) 1.00 (Reference) 1.21 (0.65-2.27) 
90-day 1.00 (Reference) 1.18 (0.81-1.73) 1.00 (Reference) 1.27 (0.76-2.11) 
1-year 1.00 (Reference) 1.17 (0.84-1.62) 1.00 (Reference) 1.22 (0.79-1.88) 
5-year 1.00 (Reference) 1.27 (0.99-1.63) 1.00 (Reference) 1.22 (0.88-1.70) 
*Adjusted for age, sex, comorbidities, hospital volume, endoscopic intervention and ulcer history 
**Adjusted for propensity score, matched for age, sex, comorbidities, hospital volume, endoscopic 
intervention and ulcer history 
  25 
      Study II 
 
Study II included 282 patients with bleeding ulcer. Of these, 97 (34.4%) patients were 
assigned to the TAE group and 185 (65.6%) patients to the surgery group. Compared to the 
surgery group, the overall all-cause mortality was decreased in the TAE group (adjusted 
HR 0.66, 95% CI 0.46-0.96). The corresponding HRs for all-cause mortality within 30 
days, 90 days, 1 year and 5 years were 0.70 (95% CI 0.37-1.35), 0.69 (95% CI 0.38-1.26), 
0.88 (95% CI 0.53-1.47) and 0.67 (95% CI 0.59-1.00), respectively (Table 4a). The risk of 
re-bleeding was higher in the TAE group compared to the surgery group (HR 2.48, 95% CI 
1.33-4.62) (Table 4b). The median length of hospital stay was shorter in the TAE group 
compared to the surgery group (8 versus 16 days), and the acceleration factor (AF) 
comparing median hospital stay in the TAE-group and the surgery group adjusted for 
confounders was 0.59 (95% CI 0.45-0.77) (Table 4c). The frequency of complications was 
lower in the TAE-group (8.3% versus 32.2%).  
Taken together, this study indicated that TAE compares favourably with surgery for 
refractory peptic ulcer bleeding. A better prognosis, shorter length of hospital stay and 
fewer complications outweigh the higher risk of re-bleeding. Thus, TAE could be 
recommended as first-line treatment for many peptic ulcer patients. 
Table 4a. Surgery or transcatheter arterial embolisation (TAE) for refractory 
peptic ulcer bleeding and risk of all-cause mortality, expressed as hazard ratios 
(HR) and confidence intervals (CI).  
 
Surgery group TAE group 
  Adjusted HR* (95% CI) Adjusted HR* (95% CI) 
Overall mortality 1.00 (reference) 0.66 (0.46-0.96) 
30 day mortality 1.00 (reference) 0.70 (0.37-1.35) 
90 day mortality 1.00 (reference) 0.69 (0.38-1.26) 
1 year mortality 1.00 (reference) 0.88 (0.53-1.47) 
5 year mortality 1.00 (reference) 0.67 (0.45-1.00) 
 
Table 4 b. Surgery or transcatheter arterial embolisation (TAE) for peptic ulcer 
bleeding and risk of re-bleeding and re-intervention, expressed as HR and CI. 
 
Surgery group TAE group 
  Adjusted HR* (95% CI) Adjusted HR* (95% CI) 
Re-bleeding 1.00 (reference) 2.48 (1.33-4.62) 
Re-intervention 1.00 (reference) 5.41 (2.49-11.76) 
* Adjusted for age, sex, former ulcer history, comorbidity (Charlson Index) and calendar period. 
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Table 4 c. 
Surgery or TAE for peptic ulcer bleeding and duration of hospital stay 
after the procedure, expressed as acceleration factor (AF) and CI.  
 
Surgery group TAE group 
  Adjusted AF (95% CI) Adjusted AF (95% CI) 
Duration of hospital stay 1.00 (reference) 0.59 (0.45-0.77)  
* Adjusted for age, sex, former ulcer history, comorbidity (Charlson Index) and 
calendar period. 
 
Study III 
This study included 20,294 gastric bypass patients. Diabetes and peptic ulcer history were 
associated with increased risks of marginal ulcer (HR 1.26, 95% CI 1.03-1.55 and HR 2.70, 
95% CI 1.81-4.03 respectively), while hyperlipidaemia, hypertension and chronic 
obstructive pulmonary disease were not. PPI users had an increased risk of marginal ulcer 
(HR 1.37, 95% CI 1.17-1.60) (Table 5). Aspirin and NSAID consumption below or equal to 
the median level was followed by decreased risk of marginal ulcer (HR 0.56, 95% CI 0.37-
0.86 and HR 0.30, 95% CI 0.24-0.38), while aspirin and NSAID use above the median 
level had an increased risk and no association with marginal ulcer, respectively (HR 1.90, 
95% CI 1.41-2.58 and HR 0.90, 95% CI 0.76-1.87). Selective serotonin re-uptake inhibitor 
use below or equal to median level had decreased risk of marginal ulcer (HR 0.50, 95% CI 
0.37-0.67), while use above the median entailed increased HR (HR 1.26, 95% CI 1.01-
1.56).  
Taken together, diabetes and peptic ulcer history seem to be risk factors for marginal ulcer, 
but not hyperlipidaemia, hypertension, or chronic obstructive pulmonary disease. Lower 
doses of aspirin, NSAIDs and selective serotonin re-uptake inhibitors might not increase 
the risk, while higher doses of aspirin might. The association with PPI is likely to be due to 
confounding by indication. 
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Table 5. Risk of developing marginal ulcer after gastric bypass 
surgery for obesity in Sweden 2006-2011, expressed as hazard 
ratios (HR) and confidence intervals (CI) 
  HR* 95% CI 
Diabetes 1.26 (1.03-1.55) 
Hyperlipidaemia 1.23 (0.95-1.59) 
Hypertension 1.17 (0.97-1.43) 
Chronic obstructive pulmonary disease 0.55 (0.26-1.17) 
Ulcer history 2.70 (1.81-4.03) 
Proton pump inhibitor use 1.37 (1.17-1.60) 
Aspirin use 1.11 (0.86-1.44) 
Non-steroid anti-inflammatory drug use 0.56 (0.48-0.66) 
Selective serotonin re-uptake inhibitor use 0.83 (0.69-1.00) 
*Adjusted for sex, age, diabetes, hyperlipidaemia, hypertension, chronic 
obstructive pulmonary disease and ulcer history when applicable 
 
 
Study IV 
Study IV included 29 032 patients with peptic ulcer who had had H. pylori eradication. 
Delays in H. pylori eradication after peptic ulcer diagnosis time-dependently increased the 
risk of recurrent ulcer, and even more so for complicated ulcer, starting from delays of 8-30 
days (Table 6). Longer delays (61-365 days) also seemed to increase gastric cancer risk. 
Compared to eradication within 7 days of peptic ulcer diagnosis, eradication within 31-60 
days had a HR of recurrent ulcer of 2.37 (95% CI 2.16-2.59), and a HR of complicated 
ulcer of 3.19 (95% CI 2.69-3.78). Regarding gastric cancer, a delay of 61-365 days 
corresponded with a HR of 3.64 (95% CI 1.55-8.56). 
These findings emphasise the relevance of implementing well-working strategies to 
expedite H. pylori eradication.  
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Table 6. Latency intervals between peptic ulcer and Helicobacter pylori 
eradication in relation to risk of recurrent peptic ulcer, ulcer complicated by 
bleeding or perforation and gastric cancer, expressed as hazard ratios (HR) 
and confidence intervals (CI) 
 
Recurrent ulcer 
Complicated 
ulcer 
Gastric cancer 
Latency     
interval 
Adjusted HR*            
(95% CI) 
Adjusted HR*           
(95% CI) 
Adjusted HR*           
(95% CI) 
≤ 7 days 1.00 (reference) 1.00 (reference) 1.00 (reference) 
8-30 days 1.17 (1.08-1.25) 1.55 (1.35-1.78) 0.85 (0.32-2.23) 
31-60 days 2.37 (2.16-2.59) 3.19 (2.69-3.78) 1.31 (0.31-5.54) 
61-365 days 2.96 (2.76-3.16) 4.00 (3.51-4.55) 3.64 (1.55-8.56) 
>365 days 3.55 (3.33-3.79) 6.14 (5.47-6.89) 4.71 (2.36-9.38) 
* Adjusted for age, sex, comorbidity, history of ulcer disease, use of ulcerogenic drugs 
and use of proton pump inhibitors. 
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METHODOLOGICAL CONSIDERATIONS 
Potential errors affecting the results in any direction need to be considered in any research. 
These errors can be systematic or random. The systematic errors, also called bias, can 
distort the results. There are multiple sources of bias. Information bias occurs when data 
are collected or assessed, for example when there is a misclassification of the study 
exposures or outcomes. The studies of this thesis are all register-based, and the registries 
used are well-validated. Regarding Study I-III, the Swedish Patient Registry has been 
validated to have a high sensitivity and specificity for the surgical procedures, which are 
study exposures. The registry can be expected to have somewhat lower sensitivity 
regarding less dramatic diagnoses such as for example diabetes, hypertension, 
hyperlipidaemia, and chronic pulmonary disease, which are used to define the exposure in 
Study III. It is reasonable to think that more severe forms of these conditions are registered, 
while less severe form could tend not to be. For example, the specificity of diabetes in the 
registry has been shown to be high in validation studies, while the sensitivity for the same 
diagnosis is lower 84. This can lead to an underestimation and misclassification of the 
exposure status. However, this misclassification would probably be non-differential, i.e., 
all study subjects would have the same probability of being misclassified, regardless of 
group assignment. As opposed to differential misclassification, non-differential 
misclassification does not explain associations, but instead dilutes them.  
 
In Study II, besides the well-validated Swedish Patient Registry, non-validated registries 
kept by the hospital radiology departments were used to identify the TAE-exposure. To 
minimise the risk of missing patients with an inaccurate registration in these registries, all 
patients with any code of abdominal angiography were included for further evaluation, 
regardless of what abdominal vessel, and regardless of registered intervention or not. This 
assured a high sensitivity. Since all medical records for these patients were scrutinised, and 
patients with other indications were excluded, the specificity for the exposure definition 
was close to 100%.  
Selection bias can occur in the sampling of study participants, and although mainly a 
problem for case-control studies, this can also be a problem in cohort studies, for example 
due to differential levels of loss to follow-up between exposure groups. This specifically is 
not a substantial problem in the present studies, since the loss to follow-up is negligible 
thanks to the completeness of the registries used. A related problem however, is the issue of 
competing risk. This can be a problem especially for other outcomes than death, since there 
is a risk that individuals are lost to follow-up in the sense that they die before the event of 
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interest occurs, which could be a problem if the mortality differs between the comparison 
groups. In study II, where the study individuals in general were old with several 
comorbidities, and where the mortality of the studied disease was considerable, the 
competing risk of death was taken into account when hazard ratios for in-hospital re-
bleeding, re-intervention and duration of hospital stay were assessed.  
 
Confounding is a bias that needs to be considered in all study designs, not the least in 
register-based cohort studies. A confounding factor is associated with both the exposure 
and the outcome, without being a link in the causal pathway between the two. An example 
is confounding by indication, which means that the characteristics of the comparison 
groups differ systematically because of the outcome under study. This is a limitation of 
Study I-II. Some of the known confounding factors are possible to adjust for in the 
statistical analyses of cohort studies, e.g. by multivariable regression, matching or 
restrictions, but there will always be a risk of confounding from known or unknown factors 
that might influence the results in one direction or the other, often referred to as residual 
confounding. In Study I, the additional propensity score analysis was used in an effort to 
handle the issue of confounding. The ideal study design for comparing two different 
treatment options and their relation to one or several outcomes is the experimental setting 
with a large randomised clinical trial (RCT). By randomly assigning very many patients 
one or the other treatment, you can theoretically avoid confounding. However, many 
exposures are not suitable for randomisation, as is true for many surgical procedures, due to 
practical or ethical considerations. Moreover, even with a randomised design, there can be a 
problem with random errors, since the number of included individuals is usually a 
problem in an RCT. Random errors are the errors that prevail even if all systematic errors 
have been accounted for. These errors are decreased with increased study size, as opposed 
to the systematic errors.  
 
If a study is well-designed and measures have been taken to avoid as many errors as 
possible, the internal validity can be considered to be high. That means that the study 
actually measures what it was intended to measure and that you can trust the result to be 
correct. The next question will be if also the external validity is satisfactory, i.e. if the 
study results can be generalised for people not included in the study. Since the studies of 
this thesis are population-based, the external validity in general might be considered to be 
good. Study I, II, and IV are based on the entire Swedish population, which facilitates 
generalisability. Study II, however, is based on the population of Stockholm County only, 
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where TAE is probably more readily available compared to some rural areas. Thus, the 
results might not be generalisable for all of Sweden (or all other populations). 
 
In all included studies of this thesis, Cox proportional hazard regression models were used 
to estimate hazard ratios. The Cox model is a popular way of analysing survival data, a key 
reason is that it does not rely on distributional assumptions for the outcome, and it is a 
robust model - the results will closely approximate the results for the correct model. A 
parametric model relies on assumptions that the survival time follows a known distribution. 
If the assumption is correct, the estimate of the regression coefficients will gain accuracy 
compared to semi-parametric or non-parametric models. A non-parametric model makes no 
assumptions of distributions. The Cox model is often referred to as semi-parametric, 
because the baseline hazard is an unspecified function. The Cox proportional hazard model 
assumes that the hazard for one individual is proportional to the hazard for any other 
individual, and that the proportionality constant is independent of time. The estimate is a 
measure of the extent to which a variable multiplicatively increases or decreases an event 
rate. There are several methods to evaluate if the proportional hazards assumption is 
fulfilled, for example graphically - through Kaplan-Meier survival curves - or by 
calculating the correlations between Schoenfelds residuals for a particular covariate and the 
ranking of individual failure time. In study II, III, and IV the proportional hazards 
assumption was evaluated and not violated.  
 
In Study I, the Cox proportional hazards assumption was evaluated, both by examining the 
“log-log”-plots and by calculating the correlation between Schoenfelds residuals for a 
covariate, and the ranking of individual failure time. Most variables met the assumption, 
but not all. When addressing the issue of a non-fitting model, there are different options. 
One option is to abandon the model in favour of another. Another option is to fit the non-
proportional variable in a stratified model. In Study I, an additional propensity score model 
was planned a priori, to take the issue of confounding by indication into account. This 
model was adjusted for all variables included in the regression model. The propensity score 
model showed similar results as did the Cox proportional hazards model. Different survival 
time periods were analysed in both models, and the different calendar periods were 
analysed separately in a stratified model.  
 
In Study II, parametric accelerated failure time (AFT) models were used to estimate the 
association between TAE or surgery and the outcome length of hospital stay. In the AFT 
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model, the effect of a covariate is to accelerate or decelerate the course of an event by some 
constant (the acceleration factor, AF), in this case the length of hospital stay. Whereas the 
Cox models compared hazards, the AFT-model compared median survival time. 
 
In Study IV, calculations of the attributable risk were performed. Although such 
estimations assume causality, which cannot be claimed, this can be used to indicate the 
proportion of outcomes that theoretically could be avoided by eliminating the specific 
exposure. 
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GENERAL DISCUSSION 
Study I and II 
The results of this thesis suggest that there are no major differences in survival in relation to 
operation method in patients that undergo surgery for peptic ulcer bleeding. The results 
indicate better survival after TAE compared to surgery in these patients.  
A major limitation of both studies is the risk of confounding. It is reasonable to think that 
clinicians are more prone to allocate older patients with several comorbidities to the 
seemingly less traumatic treatment option, i.e., less extensive surgery rather than more 
extensive surgery, and similarly to radiologic intervention (TAE) rather than surgery. This 
is supported by the distribution of co-morbidities. In the statistical models, age and co-
morbidity were therefore adjusted for along with other relevant clinical factors, and in study 
I we also added a propensity score analysis in an effort to reduce confounding. Residual 
confounding can of course not be excluded. Another limitation of study I is the lack of 
TAE-data, which is a possible confounder. The resulting error is more likely be a type II 
error, by diluting the risk estimates. 
Strengths of Study I and II are the population-based design which makes them 
generalisable, and the completeness of follow-up. The sample size of both studies also 
exceeds other published studies within the same topic. In both studies, the two emergency 
treatment alternatives for peptic ulcer bleeding that were compared can roughly be 
described as one less extensive/invasive with higher risk of re-bleeding and one that is more 
extensive/invasive with lower risk of re-bleeding. Since both short-term and long-term 
mortality among these patients usually is not re-bleeding, but rather respiratory or 
cardiovascular events,89 it seems reasonable to advocate the less extensive approaches in 
most patients.  
 
Study III  
The results of this study support some earlier suggestions about the aetiology of marginal 
ulcer. Earlier literature showed contradictory results regarding diabetes, but this study of 
over 20 000 patients undergoing gastric bypass for obesity suggests that it actually is a risk 
factor for developing marginal ulcer.  The increased risk in patients with a history of peptic 
ulcer was also reasonably convincing. However, it is unclear whether this is related to H. 
pylori or some other, endogenous factor. The findings indicating that low doses of NSAIDs 
and SSRIs could have some protective effect were rather new, and this could be an 
interesting area for further research in order to understand the mechanisms behind the 
development of this common surgical complication.  
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A limitation of Study III is the risk of misclassification of exposure or outcome. Regarding 
the exposures of different drugs, patient compliance to prescriptions is not known, and 
over-the–counter use of NSAIDs could not be accounted for. Most smokers do not have a 
chronic obstructive pulmonary disease, at least not until later in life, so this proxy probably 
includes the most severe cases of tobacco use, but far from all smokers. The coding of 
marginal ulcer after gastric bypass surgery in the Swedish Patient Registry has not been 
validated. However, in our sensitivity analyses, the estimates were similar. Nevertheless, 
these sources of error should be random and would thus dilute the associations, and not 
explain them. There is also a small risk of confounding of indication regarding the 
analgesic anti-inflammatory drugs, but since only prescribed drugs are included this is 
probably not a big problem. A difficulty in drawing conclusions regarding NSAID use is 
that the doses are not studied in any detail. Therefore, we cannot draw any conclusions 
about thresholds for risk-usage of these drugs. 
Strengths of the study include the population-based design, the very large sample-size and 
the completeness of follow-up. Moreover, several potential confounding factors were 
considered and adjusted for.  
 
Study IV – Delays in H. pylori eradication 
The results of Study IV show that even a rather short delay of H. pylori eradication therapy 
significantly increases the risk of ulcer recurrence and ulcer complications. The fact that 
eradication of H. pylori decreases risk of ulcer recurrence and gastric cancer was suggested 
in some previous research. However, in practise many patients do not receive eradication 
therapy in close proximity to the ulcer diagnosis. The new findings of this study show how 
even limited delays have major impact for the patient and thus for healthcare. Even if 
follow-up time was short for gastric cancer evaluation, a statistically significant increase in 
risk could be seen for delays of 60-365 days. Considering that approximately 70% of 
stomach ulcers and >90% of duodenal ulcers in Sweden are considered to be caused by H. 
pylori and that only 40% have received eradication therapy within 90 days55 after 
hospitalisation for bleeding peptic ulcer, a clinical problem obviously exists. This, in a 
country with rather cheap and available common healthcare for all citizens and subsidies on 
prescribed drugs. An international multi-centre study from 2012 compared adherence to 
guidelines for peptic ulcer bleedings in different European countries. In that study, only 18-
45% of patients hospitalised for peptic ulcer bleeding were tested for H. pylori.90 
A limitation of this study is the risk of misclassification of the exposure. The H. pylori 
status of all individuals in the study is based on the fact that they are diagnosed with peptic 
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ulcer and have received eradication therapy. The definition of eradication therapy was 
based on the treatment recommendations in Sweden, and on the assumption that these 
antibiotics in combination with a PPI prescription are not commonly used for other 
indications than H. pylori eradication. The misclassification would probably be non-
differential and thus dilute the results, instead of explaining them.  
 
Another limitation is that we had no data on medication before start of the Prescribed Drugs 
Registry in 2005, and we therefore do not know whether there have been earlier attempts to 
treat H. pylori in these individuals, which could be considered a potential confounding 
factor. Information on smoking habits was not available, but chronic obstructive pulmonary 
diseases and cardiovascular diseases were included in the models as comorbid conditions, 
which should reduce any confounding effect. There is a possibility that some ulcer 
diagnoses in the Swedish Patient Registry within short time from the index ulcer represent 
physicians referring to the index diagnosis. This potential misclassification would probably 
also be non-differential – or possibly more common among the patients receiving early 
treatment, since several visits to doctors with the ulcer being considered, would 
theoretically increase the chance of remembering the eradication therapy. In both cases, 
estimates would be diluted instead of enhanced.  
 
The reasons for delays of H. pylori eradication therapy could be several. One reason can be 
false negative test results. False negative tests for H. pylori is especially a risk with ongoing 
bleeding – which has been shown in studies. Another reason for a negative test result could 
be that some patients have been using PPI prior to the test. It is also possible that physicians 
simply forget to test and/or treat H. pylori, and also that the patient for some reason choose 
not to collect the prescribed medication. In Sweden, both surgeons and gastroenterologists 
perform gastrointestinal endoscopy, surgeons mostly in an emergency setting. If an H. 
pylori test has not been performed at the emergency endoscopy in the surgery clinic, 
patients are sometimes referred for this, and general follow-up, at the gastroenterology 
outpatient clinic, which can also be a reason for eradication delays. It seems urgent to 
develop better strategies for H. pylori eradication therapy that assures that all patients 
promptly get tested and treated, regardless of setting at diagnosis.  
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CONCLUSIONS 
• In patients diagnosed with of peptic ulcer bleeding where surgery is the remaining 
treatment, less radical surgery with over-sewing of the ulcer is probably sufficient in 
most patients, and more radical surgery with resection might not be required. 
• In patients diagnosed with peptic ulcer bleeding where endoscopic intervention fails 
to achieve haemostasis, transcatheter arterial embolisation (TAE) can be a first-line 
treatment at centres with experience of this procedure. 
• Diabetes and former ulcer history seem to be risk factors for marginal ulcer after 
gastric bypass surgery for obesity, while hyperlipidaemia, hypertension and chronic 
obstructive pulmonary disease might not be associated with this complication.  
• Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAID) below the 
median dose might decrease the risk of marginal ulcer, while aspirin and NSAID 
use above the median might increase the risk and not be associated with marginal 
ulcer, respectively.  
• Use of serotonin re-uptake inhibitor below the median dose might decrease the risk 
of marginal ulcer, while use above the median dose might increase this risk. 
• Delays in H. pylori eradication after peptic ulcer diagnosis seem to increase the risk 
of recurrent ulcer and, even more so, of ulcer complications in a time-dependant 
manner.  
• Delays of 3 months to 1 year in H. pylori eradication after peptic ulcer diagnosis 
might also increase the risk of gastric cancer.  
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CLINICAL IMPLICATIONS AND FUTURE RESEARCH 
Clinical decision-making in a situation with massive bleeding from a peptic ulcer will 
continue to be a challenge for physicians. With modern resuscitation, pharmacological 
peptic ulcer treatment, effective endoscopic interventions and the addition of TAE, our 
findings support the “as little as possible” regimen. This doctoral thesis implies that TAE is 
better than surgery for patients who cannot be managed with endoscopic intervention. A 
randomised multicentre trial comparing TAE and surgery would be desirable, but practical 
and ethical aspects make this very difficult in practice. Since it seems safe to conclude that 
TAE is an important tool in these cases, a 24-hour availability of this intervention can be 
recommended, which can be accomplished for example by an ambulatory service between 
hospitals. An interesting topic for future studies is to assess the value of prophylactic TAE 
in selected cases after endoscopy, preferably in in a randomised multicentre study. Efforts 
have been made to study this, but not in a larger scale.  
 
Regarding aetiology and treatment of marginal ulcer after gastric bypass surgery, many 
questions remain to be answered. The role of H. pylori is for example unclear, and 
endogenous patient factors are not well studied. Our findings regarding a potential 
protective effect of drugs affecting inflammation and coagulation is an interesting topic for 
further studies examining potential mechanisms.  
 
Evidence-based guidelines recommend testing and treating for H. pylori in patients with 
peptic ulcer disease. However, the adherence to these recommendations seem to be poor, 
and the findings of this thesis emphasise the clinical consequences of this. Actions need to 
be taken to improve the compliance to guidelines, including clinical routines, ensuring the 
quality of tests and monitoring of antibiotic resistance of H. pylori.   
Finally, it would be desirable to combine the power of nationwide registries with the 
availability of detailed clinical data by establishing a Swedish quality registry for 
endoscopy, with prospective data collection. This would facilitate future studies and 
eventually improve the management of peptic ulcer disease.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Magsår definieras som ett sår i magsäckens eller tolvfingertarmens slemhinna som är mer 
än 3-5 millimeter i diameter och sträcker sig ned till muskellagret i väggen. Kunskapen om, 
och behandlingen av magsår har närmast revolutionerats under de senaste 30 åren. Från att 
man har ansett att magsår berodde på för mycket magsyra och psykisk stress, vet vi nu att 
ungefär 70 % av såren i magsäcken och 90 % av såren i tolvfingertarmen beror på en 
bakterieinfektion som är fullt behandlingsbar med antibiotika tillsammans med medicin 
mot magsyra. Denna så kallade ”magsårsbakterie” kallas Helicobacter pylori (H. pylori) 
och förekommer i magsäcken hos ungefär hälften av världens befolkning även om den inte 
hos alla orsakar magsår. Den näst vanligaste orsaken till magsår är användandet av vissa 
vanligt förekommande läkemedel mot inflammation eller smärta eller som 
blodförtunnande, t.ex. acetylsalicylsyra.  
 
Behandling av magsår består vanligen av en veckas kur med två antibiotika mot H. Pylori i 
kombination med en magsyrahämmande medicin. På så sätt blir de allra flesta patienter av 
med bakterien. I de fall där läkemedel har orsakat magsåret, ska man om möjligt avbryta 
den läkemedelsbehandlingen. Om det inte är möjligt bör medicinen bytas mot något mindre 
skadligt och/eller kompletteras med magsårsskyddande läkemedel. De allra flesta fall av 
magsår behandlas i öppenvård, men ibland leder magsår till komplikationer, som blödning 
(vanligast) eller att det går hål (brustet magsår). Trots att insjuknandet i magsår minskat 
under senare år, har antalet komplikationer till magsår inte minskat, åtminstone inte i 
samma takt. Detta beror sannolikt på att de patienter som löper störst risk att insjukna ofta 
är äldre och har flera andra samtidiga sjukdomar.  
 
Vid blödande magsår görs i första hand åtgärder i samband med gastroskopiundersökning, 
via en lång böjlig slang med kamera och kanaler för olika tillbehör. Detta stoppar 
blödningen i mer än 9 av 10 fall. Hos resterande patienter har länge det enda återstående 
alternativet varit operation. Men dödligheten är hög i samband med den belastning kirurgi 
för blödande magsår innebär i denna akuta situation. Det har saknats studier som jämför 
resultaten efter olika omfattning av det kirurgiska ingreppet. De studier som finns 
genomfördes dessutom innan den moderna magsårsbehandlingen gjort sitt inträde, när 
kirurgi fortfarande var en del i behandling av själva magsårssjukdomen – inte bara av den 
akuta blödningen. I Studie I ville vi därför undersöka om det är någon skillnad i överlevnad 
hos de patienter där man tar bort delar av magsäck och tolvfingertarm (mer omfattande 
operation) jämfört med dem där man bara sätter stygn över själva blödningen (mindre 
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omfattande operation). Vi använde information från Socialstyrelsens patientregister för åren 
1987-2008 och kunde inkludera 4163 patienter som opererats för blödande magsår och 
sedan jämföra de två operationsmetoderna. Ingen skillnad i 5-årsöverlevnad kunde ses över 
hela studieperioden, men dödligheten var antytt högre efter mer omfattande operation 
jämfört med mindre omfattande operation under den senare halvan av studieperioden 
(relativ risk [HR] 1.27, 95 % konfidensintervall [CI] 0.99-1.63).  
 
Ett alternativ till kirurgisk behandling av blödande magsår, som använts i ökande 
utsträckning under de senaste 20 åren, är att stoppa blodflödet till magsåret via en kateter 
införd i ett större blodkärl, så kallad transarteriell kateter embolisering (TAE). Det går till 
så att man sticker in i en röntgenkateter via en pulsåder i ljumsken och för katetern uppåt 
via kroppspulsådern och ut till det blödande kärlet i anslutning till magsåret. Sedan pluggas 
det blodkärlet igen så att flödet till magsåret förhoppningsvis upphör. Det har dock saknats 
större studier på hur väl den här metoden står sig i jämförelse med den mer beprövade 
operationen. I Studie II ville vi därför jämföra överlevnad, komplikationer, risk för ny 
blödning och vårdtid på sjukhus för de patienter som behandlades med TAE jämfört med 
kirurgi. Vi använde information från patientregistret, register på röntgenavdelningar, samt 
medicinska journaler för att identifiera och jämföra patienter som genomgått TAE (97 
individer) eller kirurgi (185 individer) för blödande magsår i Stockholms län under åren 
2000-2014. Jämfört med kirurgi var TAE associerat med en 34 % lägre dödlighet (HR 0.66, 
95 % CI 0,46–0,96) och med ett lägre antal komplikationer (8,3% jämfört med 32,2%). 
Vårdtiden var också kortare vid TAE (mediantid 8 jämfört med 16 dygn), men risken för 
förnyad blödning var klart högre (HR 2.48, 95 % CI 1,33–4,62). 
 
En annan typ av svårbehandlat magsår är det som kan uppkomma efter kirurgi för 
behandling av fetma. Den ökande förekomsten av fetma och de positiva långvariga effekter 
som påvisats av kirurgi mot fetma avseende följdsjukdomar och dödlighet, gör att denna 
behandling ökat snabbt. Det vanligaste ingreppet är en förbikoppling av magsäcken, så 
kallad gastric bypass, där maten dirigeras förbi stora delar av magsäcken och hela 
tolvfingertarmen (bild 1, sida 2). En av de vanligaste komplikationerna till detta ingrepp är 
en särskild variant av magsår som kallas marginalsår. Dessa uppstår intill kopplingen 
mellan den nyskapade mindre magsäcksfickan och tunntarmen, nästan alltid på 
tunntarmssidan. Såren är ofta mer svårläkta än vanliga magsår. Orsakerna till varför såren 
uppstår är till stora delar okända. Tidigare har detta studerats endast i mindre studier från 
enskilda kirurgiska centra. I Studie III ville vi identifiera riskfaktorer för marginalsår efter 
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gastric bypass kirurgi genom att studera en stor grupp opererade patienter från hela Sverige. 
Vi använde svenska patientregistret och fann 20 294 personer som genomgått gastric 
bypass kirurgi för fetma mellan åren 2006 och 2011 Genom patientregistret och 
läkemedelsregistret kunde vi undersöka om vissa på förhand möjliga riskfaktorer verkade 
påverka risken för marginalsår. Diabetes (HR 1,26, 95 % CI 1,03–1,55) och tidigare 
magsårssjukdom (HR 2,70, 95 % CI 1,81–4,03) ökade risken, medan höga blodfetter, högt 
blodtryck och kronisk lungsjukdom (som ofta drabbar rökare) inte medförde ökad risk. 
Användning av acetylsalicylsyra och antiinflammatoriska smärtstillande läkemedel verkade 
ge något lägre risk för marginalsår i låga doser, medan högre doser istället gav ökad eller 
ingen skillnad i risk. 
 
Trots att H. pylori kan orsaka magsår och även öka risken för cancer i magsäcken och är en 
viktig behandling av magsår, så har studier visat att många patienter av någon anledning 
inte behandlas mot infektionen i nära anslutning till att de vårdats för blödande magsår. Det 
är oklart om denna fördröjning medför risker, varför vi i Studie IV undersökte om 
fördröjning i behandlingen av H. pylori med olika tidsintervall efter magsårsdiagnos 
påverkar risk för återfall i magsår, magsårskomplikationer och magsäckscancer. Vi använde 
information från patientregistret och läkemedelsregistret och kunde finna 29 032 personer 
som fått diagnosen magsår och erhållit behandling mot H. pylori under åren 2005–2013. 
Sedan användes patientregistret och cancerregistret för att se hur risken för att få nytt 
magsår, komplikationer till magsår, eller magsäckscancer påverkades av olika grader av 
försenad behandling. Vi kunde se att risken för nytt magsår (HR 1,17, 95 % CI 1,08–1,25) 
och ännu mer dess komplikationer (HR 1,55, 95 % CI 1,35–1,78), ökade redan vid 8-30 
dagars försening av behandling. Ju längre fördröjning, desto högre risker. Dessutom fann vi 
att längre försening (61–365 dagar) även verkade öka risken för magsäckscancer (HR 3,64, 
95% CI 1,55–8,56). 
 
Slutsatser vid dragit av studieresultaten: 
I: Mindre omfattande operation tycks ge minst lika bra överlevnad som mer omfattande 
kirurgi för blödande magsår där åtgärder vid gastroskopi inte kunnat stoppa blödningen, 
varför den förstnämnda metoden kan rekommenderas. 
II: TAE tycks vara bättre än kirurgi i behandlingen av blödande magsår. Även om patienter 
som behandlats med TAE har större risk för ny blödning, så var överlevnaden bättre med 
färre allvarliga komplikationer och kortare vårdtid efter TAE jämfört med kirurgi.   
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III: Diabetes och tidigare magsår verkar öka risken för marginalsår efter fetmakirurgi med 
gastric bypass, medan högt blodtryck, höga blodfetter och kronisk lungsjukdom inte tycks 
öka denna risk. Användning av lägre doser antiinflammatoriska läkemedel tycks inte öka 
risken, men högre doser verkar göra det.  
IV: Att fördröja behandling för H. pylori ökar risken att återinsjukna i magsår och ännu 
mer för att få komplikationer som blödning eller brustet magsår på ett tidsberoende sätt. 
Om behandlingen skjuts upp till intervallet mellan 2 månader och 1 år efter 
magsårsdiagnosen, verkar även risken för cancer i magsäcken öka.  
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